New Biomarkers of Bone Mineral Metabolism as Cardiovascular Risk Factors in Chronic Kidney Disease Patients
NCT ID: NCT02808572
Last Updated: 2022-01-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
250 participants
INTERVENTIONAL
2013-03-12
2031-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of Cardiovascular Risk Factors Linked to Renal Failure Progression
NCT00608998
The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease
NCT05214872
The CPH-MBD Cohort
NCT07193056
A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients
NCT01236820
Renal and Vascular Phenotypic Characterization of Patients With Enamel Renal Syndrome Due to a Pathogenic Variant of the FAM20A Gene and Pathophysiological Study of Ectopic Calcifications
NCT07285421
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cardiovascular risk evaluation
Measurement at inclusion of plasma osteoprotegerin level, plasma fibroblast growth factor 23 level, vascular calcification score and record of cardiovascular events during the 3 year follow-up
Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Vascular calcification score
measurement of vascular calcification score by multidetection computerized tomography
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Plasma osteoprotegerin level
dosage of plasma osteoprotegerin
Plasma fibroblast growth factor 23 level
dosage of plasma fibroblast growth factor 23
Vascular calcification score
measurement of vascular calcification score by multidetection computerized tomography
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patient with chronic renal failure defined by glomerular filtration rate (GFR) but without dialysis therapy
Exclusion Criteria
* Patient with chronic renal failure requiring dialysis therapy
18 Years
95 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospital, Montpellier
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jean-Paul CRISTOL, Prof
Role: PRINCIPAL_INVESTIGATOR
CHU Lapeyronie, Department of Biochemistry and Hormonology, Montpellier, FRANCE
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AIDER
Montpellier, , France
CHU Montpellier, Cardiology department
Montpellier, , France
CHU Montpellier, Endocrinology department
Montpellier, , France
CHU Montpellier, Intensive care unit
Montpellier, , France
CHU Montpellier, Internal medicine department
Montpellier, , France
CHU Montpellier, Nephrology department
Montpellier, , France
AIDER
Saint-Jean-de-Védas, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Lotfi Chalabi, Dr
Role: primary
Eric Renard, Prof
Role: primary
Hélène Leray-Moragues, Dr
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UF9125
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.